BioSpace News Archive

SOPHiA GENETICS, a cloud-native healthcare technology company and a leader in data-driven medicine, announced that Kepler Uniklinikum, Austria’s second largest hospital, is live on SOPHiA GENETICS’ platform.

Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of DYRK/CLK kinases, has entered a collaboration with Novo Nordisk to develop drug candidates for the treatment of diabetes.

Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.

Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer, effective July 8, 2024.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat with David S. Perlin, PhD, a recognized expert in antifungals.

Clario, a leading provider of technologies and endpoint data solutions for clinical trials, announced the U.S. Food and Drug Administration 510 clearance for its SpiroSphere® with the wireless COR-12 Electrocardiogram device.

UCB, a global biopharmaceutical company, will present results from three studies for CIMZIA®, a PEGylated fragment crystalized -free tumor necrosis factor inhibitor, for women of childbearing age living with chronic immune-mediated diseases and people with rheumatoid arthritis and high rheumatoid factor levels.

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.

Syros Pharmaceuticals announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome and the opportunity for tamibarotene to transform the care of newly diagnosed patients with RARA gene overexpression.

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate - technology, announced the appointment of Ulf Grawunder, Ph.D. to its scientific advisory board.